Download PDF
Semin Reprod Med 2003; 21(3): 295-300
DOI: 10.1055/s-2003-43307
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

21-Hydroxylase-Deficient Nonclassic Adrenal Hyperplasia: The Great Pretender

Carlos Moran1 , Ricardo Azziz2
  • 1Health Research Council, Mexican Institute of Social Security, Mexico City, Mexico
  • 2Division of Reproductive Biology and Endocrinology, Department of Obstetrics and Gynecology, and Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama
Further Information

Publication History

Publication Date:
31 October 2003 (online)

    Permissions and Reprints

ABSTRACT

Polycystic ovary syndrome (PCOS) affects about 4 to 6% of women of reproductive age and accounts for at least 75% of hyperandrogenic patients. PCOS is diagnosed by the presence of oligo-ovulation and hyperandrogenism after the exclusion of related disorders, such as 21-hydroxylase-deficient nonclassic adrenal hyperplasia (NCAH). In turn, NCAH is a homozygous recessive disorder, diagnosed by a corticotropin-stimulated 17-hydroxyprogesterone (17-HP) level greater than10 ng/mL (30.3 nmol/L) and confirmed by genotyping of the CYP21 gene. The prevalence of NCAH is approximately 50 times less than that of PCOS, affecting between 1 and 10% of hyperandrogenic women, depending on ethnicity. However, it is generally difficult to distinguish NCAH from PCOS solely on clinical grounds, as both demonstrate varying degrees of hyperandrogenism and ovulatory dysfunction. Most PCOS patients have insulin resistance, in contrast to those with NCAH. Likewise, polycystic ovaries are observed in up to 40% of NCAH patients. Both disorders have a strong familial component. The only method that allows the separation of NCAH from PCOS patients is the measurement of 17-HP levels. In conclusion, PCOS and NCAH have differences in prevalence and pathophysiology. However, because the disorders have significant clinical and hormonal similarities, the measurement of 17-HP, preferably basally as a screening method, should be incorporated into the evaluation of all hyperandrogenic patients.

KEYWORDS

Polycystic ovary syndrome - adrenal hyperplasia - hyperandrogenism

REFERENCES

  • 1 Zawadzki J K, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, eds. Polycystic Ovary Syndrome Boston: Blackwell Scientific 1992: 377-384
    Google Scholar
  • 2 Azziz R, Boots L R, Parker Jr R C, Bradley Jr E, Zacur H A. 11β-Hydroxylase deficiency in hyperandrogenism.  Fertil Steril . 1991;  55 733-741
    PubMedGoogle Scholar
  • 3 Azziz R, Bradley Jr L E, Potter H D, Boots L R. 3β-Hydroxysteroid dehydrogenase deficiency in hyperandrogenism.  Am J Obstet Gynecol . 1993;  168 889-895
    PubMedGoogle Scholar
  • 4 Joehrer K, Geley S, Strasser-Wozak E MC. et al . CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11β-hydroxylase deficiency.  Hum Mol Genet . 1997;  6 1829-1834
    CrossrefPubMedGoogle Scholar
  • 5 Moran C, Potter H D, Reyna R, Boots L R, Azziz R. Prevalence of 3β-hydroxysteroid dehydrogenase deficient nonclassic adrenal hyperplasia in hyperandrogenic women with adrenal androgen excess.  Am J Obstet Gynecol . 1999;  181 596-600
    PubMedGoogle Scholar
  • 6 Azziz R, Hincapie L A, Knochenhauer E S, Dewailly D, Fox L, Boots L R. Screening for 21-hydroxylase deficient non-classic adrenal hyperplasia among hyperandrogenic women: a prospective study.  Fertil Steril . 1999;  72 915-925
    CrossrefPubMedGoogle Scholar
  • 7 Moran C, Azziz R, Carmina E. et al . 21-Hydroxylase- deficient nonclassic adrenal hyperplasia is a progressive disorder.  Am J Obstet Gynecol . 2000;  183 1468-1474
    CrossrefPubMedGoogle Scholar
  • 8 Speiser P W, Knochenhauer E S, Dewailly D, Fruzzetti F, Marcondes J AM, Azziz R. A multicenter study of women with nonclassical congenital adrenal hyperplasia: relationship between genotype and phenotype.  Mol Genet Metab . 2000;  71 527-534
    CrossrefPubMedGoogle Scholar
  • 9 Bachega T S S A, Billerbeck A EC, Marcondes J AM, Madureira G, Arnhold I JP, Mendonca B B. Influence of different genotypes on 17-hydroxyprogesterone levels in patients with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency.  Clin Endocrinol (Oxf) . 2000;  52 601-607
    CrossrefPubMedGoogle Scholar
  • 10 Azziz R, Dewailly D, Owerbach D. Nonclassic adrenal hyperplasia: current concepts.  J Clin Endocrinol Metab . 1994;  78 810-815
    CrossrefPubMedGoogle Scholar
  • 11 Knochenhauer E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.  J Clin Endocrinol Metab . 1998;  83 3078-3082
    CrossrefPubMedGoogle Scholar
  • 12 Asuncion M, Calvo R M, San Millan L J, Sancho J, Avila S, Escobar-Morreale H F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain.  J Clin Endocrinol Metab . 2000;  85 2434-2438
    CrossrefPubMedGoogle Scholar
  • 13 Moran C, Tapia M C, Hernandez E, Vazquez G, Garcia-Hernandez E, Bermudez J A. Etiological review of hirsutism in 250 patients.  Arch Med Res . 1994;  25 311-314
    PubMedGoogle Scholar
  • 14 Romaguera J, Moran C, Diaz-Montes T P, Hines G A, Cruz R I, Azziz R. Prevalence of 21-hydroxylase-deficient nonclassic adrenal hyperplasia and insulin resistance among hirsute women from Puerto Rico.  Fertil Steril . 2000;  74 59-62
    CrossrefPubMedGoogle Scholar
  • 15 Sanchez L A, Knochenhauer E S, Gatlin R, Moran C, Azziz R. Differential diagnosis of clinically evident hyperandrogenism: experience with over 1000 consecutive patients. The Annual Meeting of the American Society for Reproductive Medicine, Orlando, FL, October 20-25, 2001 (Abstract O-294).  Fertil Steril . 2001;  76 S111
    CrossrefPubMedGoogle Scholar
  • 16 Speiser P W, Dupont B, Rubinstein P, Piazza A, Kastelan A, New M I. High frequency of nonclassical steroid 21-hydroxylase deficiency.  Am J Hum Genet . 1985;  37 650-657
    PubMedGoogle Scholar
  • 17 Chetkowski R J, DeFazio J, Shamonki I, Judd H L, Chang R J. The incidence of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency among hirsute women.  J Clin Endocrinol Metab . 1984;  58 595-598
    PubMedGoogle Scholar
  • 18 Azziz R, Zacur H A. 21-Hydroxylase deficiency in female hyperandrogenism: screening and diagnosis.  J Clin Endocrinol Metab . 1989;  69 577-584
    CrossrefPubMedGoogle Scholar
  • 19 Kuttenn F, Couillin P, Girard F. et al . Late-onset adrenal hyperplasia in hirsutism.  N Engl J Med . 1985;  313 224-231
    PubMedGoogle Scholar
  • 20 Motta P, Catania A, Airaghi L, Mangone I, Cantalamessa L, Zanussi C. Prevalence of late-onset adrenal hyperplasia in postmenarchal hirsutism.  J Endocrinol Invest . 1988;  11 675-678
    PubMedGoogle Scholar
  • 21 Innanen V T, Vale J M. Assessment of the one hour adrenocorticotrophic hormone test in the diagnosis of attenuated 21-hydroxylase deficiency.  J Clin Pathol . 1990;  43 493-495
    PubMedGoogle Scholar
  • 22 Mithal A, Ammini A C, Godbole M M. et al . Late-onset adrenal hyperplasia in north Indian hirsute women.  Horm Res . 1988;  30 1-4
    PubMedGoogle Scholar
  • 23 Eldar-Geva T, Hurwitz A, Vecsei P, Palti Z, Milwidsky A, Roslër A. Secondary biosynthetic defects in women with late-onset congenital adrenal hyperplasia.  N Engl J Med . 1990;  323 855-863
    PubMedGoogle Scholar
  • 24 Khandekar S, Lata V, Dash R J. Screening for late onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency.  Indian J Med Res . 1990;  92 79-82
    PubMedGoogle Scholar
  • 25 Arnaout M A. Late-onset congenital adrenal hyperplasia in women with hirsutism.  Eur J Clin Invest . 1992;  22 651-658
    PubMedGoogle Scholar
  • 26 Goldzieher J W, Green J A. The polycystic ovary I: clinical and histologic features.  J Clin Endocrinol Metab . 1962;  22 325-338
    PubMedGoogle Scholar
  • 27 Conway G S, Honour J W, Jacobs H S. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients.  Clin Endocrinol (Oxf) . 1989;  30 459-470
    PubMedGoogle Scholar
  • 28 Franks S. Polycystic ovary syndrome: a changing perspective.  Clin Endocrinol (Oxf) . 1989;  31 87-120
    CrossrefPubMedGoogle Scholar
  • 29 Dewailly D, Vantyghem-Haudiquet M C, Sainsard C. et al . Clinical and biological phenotypes in late-onset 21 hydroxylase deficiency.  J Clin Endocrinol Metab . 1986;  63 418-423
    PubMedGoogle Scholar
  • 30 Carmina E, Koyama T, Chang L, Stanczyk F Z, Lobo R A. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?.  Am J Obstet Gynecol . 1992;  167 1807-1812
    PubMedGoogle Scholar
  • 31 Levin J H, Carmina E, Lobo R A. Is the inappropriate gonadotropin secretion of patients with the polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia?.  Fertil Steril . 1991;  56 635-640
    PubMedGoogle Scholar
  • 32 Moran C, Knochenhauer E, Boots L R, Azziz R. Adrenal androgen excess in hyperandrogenism: relation to age and body mass.  Fertil Steril . 1999;  71 671-674
    CrossrefPubMedGoogle Scholar
  • 33 Huerta R, Dewailly D, Decanter C, Knochenhauer E S, Boots L R, Azziz R. 11β-Hydroxyandrostenedione and Δ5-androstenediol as markers of adrenal androgen production in patients with 21-hydroxylase deficient nonclassic adrenal hyperplasia.  Fertil Steril . 1999;  72 996-1000
    CrossrefPubMedGoogle Scholar
  • 34 New M I, Lorenzen F, Lerner A J. et al . Genotyping steroid 21-hydroxylase deficiency: hormonal reference data.  J Clin Endocrinol Metab . 1983;  57 320-326
    CrossrefPubMedGoogle Scholar
  • 35 Auchus R J, Lee T C, Miller W L. Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer.  J Biol Chem . 1998;  273 3158-3165
    CrossrefPubMedGoogle Scholar
  • 36 Azziz R, Rafi A, Smith B R, Bradley Jr L E, Zacur H A. On the origin of the elevated 17-hydroxyprogesterone levels after adrenal stimulation in hyperandrogenism.  J Clin Endocrinol Metab . 1990;  70 431-436
    PubMedGoogle Scholar
  • 37 Dunaif A, Segal K R, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome.  Diabetes . 1989;  38 1165-1174
    CrossrefPubMedGoogle Scholar
  • 38 Legro R S, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome.  J Clin Endocrinol Metab . 1998;  83 2694-2698
    CrossrefPubMedGoogle Scholar
  • 39 Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.  J Clin Endocrinol Metab . 1999;  84 165-169
    CrossrefPubMedGoogle Scholar
  • 40 Talbott E, Clerici A, Berga S L. et al . Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study.  J Clin Epidemiol . 1998;  51 415-422
    CrossrefPubMedGoogle Scholar
  • 41 Speiser P W, Serrat J, New M I, Gertner J M. Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency.  J Clin Endocrinol Metab. 1992;  75 1421-1424
    CrossrefPubMedGoogle Scholar
  • 42 Kahsar-Miller M D, Nixon C, Boots L R, Go R C, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS.  Fertil Steril . 2001;  75 53-58
    CrossrefPubMedGoogle Scholar
  • 43 Miller W L. Molecular biology of steroid hormone synthesis.  Endocr Rev . 1988;  9 295-318
    CrossrefPubMedGoogle Scholar
  • 44 Miller W L. Genetics, diagnosis and management of 21-hydroxylase deficiency.  J Clin Endocrinol Metab . 1994;  78 241-246
    CrossrefPubMedGoogle Scholar
      >